Q-omics provides the consensus-scored NTN1 profile across patient tissues and cancer cell-line models. NTN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NTN1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NTN1 RNA expression shows 17,526 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where NTN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTN1 survival associations across molecular data types. NTN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTN1 RNA expression–survival associations across cancer types. High NTN1 expression shows unfavorable associations in MESO, BLCA and UVM, but favorable associations in HNSC, KIRC and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for NTN1 RNA expression.
This table summarizes NTN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NTN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTN1 shows lower tumor expression in COAD, KIRC, THCA, BLCA and KIRP and higher tumor expression in KICH. The COAD box plot shows higher NTN1 RNA expression in normal versus tumor tissue (log2 FC = −2.394, t-test p < 0.001).
This table shows molecular features associated with NTN1 in patient tissues and cancer cell lines. In patient samples, NTN1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
